UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Brisbane, Australia.
Central Microbiology, Pathology Queensland, Royal Brisbane & Women's Hospital, Brisbane, Australia.
Microb Drug Resist. 2022 Jul;28(7):795-805. doi: 10.1089/mdr.2022.0035. Epub 2022 Jun 21.
An attributing factor to Enterobacterales producing extended-spectrum beta-lactamase (ESBL-E) community spread is human-to-human transmission. This systematic review and meta-analysis aimed to estimate the duration of ESBL-E carriage in the community and the rate of household transmission. Literature search was performed on PubMed, EMBASE, and Scopus. Dose-response meta-analysis was planned to model the proportion of ESBL-E carriers and household transmission over time. Twenty-six studies ( = 2,505 participants) were included. The median carriage duration was 2 months. Approximately 22% (95% confidence interval: 16-28) had persistent carriage after 12 months. Travelers had significantly shorter carriage (median 1-2 months) than discharged hospital patients (median 6 months) at all measured time points. There were insufficient data to robustly meta-analyze household transmission. Nonetheless, five longitudinal studies reported 18.4% to 35.2% of contacts acquired ESBL-E within 4 to 36 months from hospital discharge of index case. Transmission events from travelers to their contacts appeared lower. Travelers with travel-acquired ESBL-E had significantly faster decolonization rate than discharged patients, suggesting that travel-associated import of multidrug-resistant pathogen may have limited contribution to community transmission of ESBL-E. The substantial prevalence of persistent carriers warrant consideration for additional measures to mitigate exposure risk of ESBL-E from discharged patients in the community and from readmitting patients in the hospital.
肠杆菌科产生超广谱β-内酰胺酶(ESBL-E)的一个归因因素是人际传播。本系统评价和荟萃分析旨在估计社区中 ESBL-E 携带的持续时间和家庭传播的比率。在 PubMed、EMBASE 和 Scopus 上进行了文献检索。计划进行剂量反应荟萃分析,以建立 ESBL-E 携带者和家庭传播随时间的比例模型。共纳入 26 项研究(=2505 名参与者)。中位携带期为 2 个月。大约 22%(95%置信区间:16-28)在 12 个月后仍持续携带。在所有测量时间点,旅行者的携带时间明显短于出院患者(中位 6 个月)。没有足够的数据来稳健地荟萃分析家庭传播。尽管如此,五项纵向研究报告了 18.4%至 35.2%的接触者在出院后 4 至 36 个月内从指数病例中获得 ESBL-E。来自旅行者的传播事件似乎较低。从旅行者传播给接触者的 ESBL-E 患者的定植清除率明显较快,这表明旅行者获得的多药耐药病原体的传播可能对社区中 ESBL-E 的传播贡献有限。持续携带的高患病率需要考虑采取额外措施,以减轻社区中出院患者和再次入院患者中 ESBL-E 的暴露风险。